DUAL PI3K Δ/Γ INHIBITOR RP6530 IN PATIENTS WITH RELAPSED/REFRACTORY T-Cell LYMPHOMA: DOSE ESCALATION FINDINGS.

Hematological Oncology - United Kingdom
doi 10.1002/hon.2439_191
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Patients With Relapsed/Refractory T-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Outcome of Patients With Relapsed and Refractory Peripheral T Cell Lymphoma Intended for Stem Cell Transplant

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Rituximab, Bendamustine and Cytarabine (R-Bac) in Patients With Relapsed-Refractory Aggressive B- And T-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Cd19/Cd20-Redirected Bispecific Car T Cell Treatment in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Phase II Study of an AKT Inhibitor MK2206 in Patients With Relapsed or Refractory Lymphoma

Blood
BiochemistryImmunologyCell BiologyHematology
2014English

Phosphatidylinositol 3-Kinase-Δ (PI3K-δ) Is a Potential Therapeutic Target in Adult T-Cell Leukemia-Lymphoma

Biomarker Research
BiochemistryMolecular MedicineClinical Biochemistry
2018English

Durable Response With Single-Agent Acalabrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2019English

Nelarabine Treatment in Adult Patients With Refractory/ Relapsed T-Cell Acute Lymphoblastic Leukaemia/Lymphoma: Experience of a Single Centre

Gematologiya i Transfuziologiya
Hematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy